biopharma pharmacist

Jul 12, 2021 | Biopharma ESG Risks from U.S. Pricing doesn't sway our valuation

Join Morningstar, Sustainalytics and the Institute for Clinical and Economic Review (ICER) to discuss the methodology in application to a core risk facing the biopharma group: new U.S. government policies aimed at reducing drug pricing to increase access for patients.